Advertisement
Advertisement
U.S. Markets open in 4 hrs
Advertisement
Advertisement
Advertisement
Advertisement

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7235-0.0292 (-3.88%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7527
Open0.7600
Bid0.7150 x 3100
Ask0.7500 x 1000
Day's Range0.7110 - 0.7637
52 Week Range0.5490 - 3.0400
Volume957,213
Avg. Volume529,936
Market Cap40.696M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.5330
Earnings DateAug 05, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • American City Business Journals

    These 40 Mass. companies made the new Deloitte Fast 500 list

    The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.

  • PR Newswire

    Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its third quarter 2021 financial results and provides a business update.

  • PR Newswire

    Pulmatrix Announces Resolution of Contract Dispute with Cipla

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has completed an amendment to Pulmatrix's agreement with Cipla Technologies, LLC ("Cipla") for the development and commercialization of Pulmazole. The completion of the amendment resolves Pulmatrix's previously disclosed dispute with Cipla regarding the continued fu

Advertisement
Advertisement